AAO 2021: An Invite from Quidel Corporation
Shawn P. Mullen, Global KOL and Strategic Management at Quidel Corporation-Eye Health, talks about the company's plans for this year's AAO meeting
sponsored by Quidel
Quidel has been consistent with the strategy of expanding access to affordable testing, and we look forward to sharing more on these and other initiatives in the future! There continues to be both a strong need for COVID-19 testing, as well as for InflammaDry, the first and only MMP-9 test available to the ophthalmic community for ocular surface inflammation, and our QuickVue Adenoviral Conjunctivitis test that detects the presence or absence of the adenovirus.
Quidel’s products allow healthcare workers as well as corporate employees to quickly test and treat at the point of= care, which leads to improved patient outcomes and provides numerous economic benefits to the healthcare system. The InflammaDry test has recently been included as one piece of the overall puzzle to ASCRS/ESCRS Pre-Operative OSD Algorithm – an essential test prior to an elective procedure.
In 2020, Quidel rose to the challenge and responded to the largest pandemic in modern history by being the first to market a rapid SARS-CoV-2 antigen test in the US, Sofia® SARS Antigen FIA. In March 2021, Quidel received approval for its QuickVue® At-Home OTC COVID-19 Test, unlocking a new market beyond the professional segment to include retail, employee, school, and home testing. Our rapid QuickVue COVID-19 tests and our newest OTC COVID-19 at-home tests are fast (under 10 minutes), accurate, and can be done at work or at home. Clinicians can also offer QuickVue test to patients to ensure that they are not contagious, so the practice can reopen and stay open with confidence.
Booth number 1034